about
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsThe p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.Mechanisms of targeting the MDM2-p53-FOXM1 axis in well-differentiated intestinal neuroendocrine tumors.Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms
P50
Q26862544-72C13CF7-BBD5-4C8C-9EF0-91071CF5CEE2Q38403010-0C532A80-54A7-4BA3-8738-2BFA0C3733D4Q38695102-EF004A30-3A1A-4C71-A7AA-6057503AC3DCQ38752443-7B2A1CEF-3531-4DEA-9AF5-DBC475C21D48Q47140422-1E9F05B3-D3B0-4FD4-9C01-8A959EECD830Q47984767-CFC474B1-3A4D-4A40-9B06-0F4126A5DC2AQ56957529-8FB0889D-2F09-4F46-9091-DAFE52000177
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Franziska Briest
@ast
Franziska Briest
@en
Franziska Briest
@es
Franziska Briest
@nl
type
label
Franziska Briest
@ast
Franziska Briest
@en
Franziska Briest
@es
Franziska Briest
@nl
prefLabel
Franziska Briest
@ast
Franziska Briest
@en
Franziska Briest
@es
Franziska Briest
@nl
P106
P21
P31
P496
0000-0001-5969-9467